Latest News for: mpn

Edit

Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs

Nasdaq Globe Newswire 06 Dec 2025
First disclosure of PRT12396, a JAK2V617F-selective JH2 inhibitor demonstrates disease modifying potential in myeloproliferative neoplasms ... .
Edit

Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs (Prelude Therapeutics Inc)

Public Technologies 06 Dec 2025
JAK2V617F and mCALR are the two primary driver mutations responsible for disease progression and poor prognosis in the majority of MPN patients ... wave of disease-modifying therapies for MPN patients.
Edit

Incyte Celebrates the 2025 MPN Heroes®, Extraordinary Individuals and Organizations Making an Impact on the Myeloproliferative Neoplasm (MPN) Community (Incyte Corporation)

Public Technologies 05 Dec 2025
lncgte Celebrates the 2025 MPN Heroes°, Extraordinary Individuals and Organizations Making an Impact on the Mgeloproliferative Neoplasm (MPN] Community ... This gear's MPN Heroes wilt be celebrated at an event on Fridag, December 5, 2025, at the.
Edit

MPN Research Foundation Has Two Abstracts Accepted for Presentation at ASH 2025 on Research about Treating and Living with Myeloproliferative Neoplasms

PR Newswire 04 Dec 2025
About MPN Research Foundation MPN Research Foundation is dedicated to funding and advancing original research in pursuit of new treatments — and eventually a cure — for essential thrombocythemia (ET), ...
  • 1
×